[123I]4-(2-(Bis(4-fluorophenyl)methoxy)ethyl)-1-(4-iodobenzyl)piperidine (β-CIT) is used for imaging assessment of dopamine transporter density in patients with early Parkinson’s disease participating in early and late levodopa therapy for Parkinson’s disease. Here, SLC6A3 is linked to Parkinson disease.